Frontlight ResearchEarly access
TerminatedNo phase
Nanowear Heart Failure Management Multi-sensor Algorithm
Key facts
- Who runs it
- Nanowear Inc.
- Where
- Hershey, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 13 people enrolled
- Started
- 21 Aug 2019
- Ended
- 18 Jun 2024
- Type of study
- Observational
- Treatments tested
- SimpleSENSE
- Record updated
- 9 April 2026
- Why it stopped
- Logistics and low enrollment.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Subject has provided informed consent
- Male or female over the age of 18 years
- The patient is either hospitalized with a primary diagnosis of acute or was discharged with a primary diagnosis of acute heart failure within 2 weeks prior to enrollment
- NYHA functional class II-IV at time of enrollment
Who cannot take part
- Subjects who are hemodynamically unstable requiring support with intravenous vasoactive medications or mechanical circulatory support
- Subject unwilling or unable to comply with wearing the Nanowear Congestive Heart Failure Management System 12 hours daily for up to 90 days
- Subjects who are limited by angina
- Symptomatic ventricular arrhythmias within the past 6 months
- Severe aortic stenosis
- Subjects who are pregnant will be excluded from this study
Where in United States
- Penn State Health Milton S. Hershey Medical CenterHershey, United States
About the trial
What the trial wants to find out
The NanoSense study is a multi-center, prospective, non-randomized, observational, feasibility, non-significant risk study. The NanoSense study will enroll up to 500 subjects in up to 10 centers in order to collect data which includes at least 150 heart failure hospitalizations in participating subjects.The duration of the NanoSense study is expected to be 2 years. The study device is the Wearable Congestive Heart Failure Management System (WCHFS, also known as SimpleSENSE)
The group in the trial
- Heart Failure Patients
Patients with primary diagnosis as heart failure
Treatment: SimpleSENSE
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Nanowear Wearable Heart Failure Management System Multiple Sensor Algorithm Development and Validation Trial
- Record updated
- 9 April 2026